Proposal for a statutory restructuring plan
March 31, 2022 12:00 ET
|
ORPHAZYME A/S
Orphazyme A/S in restructuringCompany announcementNo. 15/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 31, 2022 – Orphazyme A/S in...
Updated Financial Calendar for 2022
March 29, 2022 07:15 ET
|
ORPHAZYME A/S
Orphazyme A/S in restructuringCompany announcementNo. 14/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 29, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH)...
Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C
March 22, 2022 06:54 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 13/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Decision to withdraw the European Marketing Authorisation Application comes ahead of...
Orphazyme A/S has filed for voluntary delisting of ADSs
March 21, 2022 17:44 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 12/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 21, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Notice of in-court restructuring proceedings of Orphazyme A/S
March 18, 2022 06:40 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 11/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 18, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Commencement of in-court restructuring of Orphazyme A/S
March 10, 2022 16:05 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 10/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Will institute a reduction of approximately 50% of current work forceIntends to...
Updated Financial Calender for 2022
March 03, 2022 03:35 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 09/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 3, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Anders Vadsholt takes over as CEO of Orphazyme
February 28, 2022 02:25 ET
|
ORPHAZYME A/S
Company announcementNo. 08/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Orphazyme announces update on regulatory review of arimoclomol in the European Union
February 23, 2022 16:05 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US))...
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
February 18, 2022 16:01 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 06/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a...